Beam Therapeutics to Participate in Upcoming May Investor Conferences
May 04, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting
May 02, 2022 16:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
March 25, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
March 08, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 06:30 ET
|
Beam Therapeutics
Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned...
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022 06:00 ET
|
Beam Therapeutics
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with...
Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones
January 09, 2022 09:00 ET
|
Beam Therapeutics
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for...
Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
December 12, 2021 09:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a...